Dataset related to article "Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery."

<p>BACKGROUND:</p> <p>Immune infiltrate impacts prognosis of several tumors. To assess the prognostic impact of tumor-infiltrating lymphocytes and macrophages in patients undergoing resection for intrahepatic cholangiocellular carcinoma (ICC).</p> <p>METHODS:</p> <p>All consecutive patients undergoing surgery for ICC between 2008 and 2016 were considered. Inclusion criteria were complete resection and follow-up &gt;&thinsp;12&nbsp;months. Tissue sections were immunostained for CD3+, CD4+, CD8+, Foxp3+, and CD68+. The number of positive cells was quantified using a computer-aided image analysis system. Different cut-off values were tested as predictors of overall survival (OS).</p> <p>RESULTS:</p> <p>Fifty-three patients were analyzed. ICC were T1 in 28 patients, multifocal in 11, and N+ in 13. After a median follow-up of 42&nbsp;months, 5-year OS was 52.1%. The following immune infiltrate values were associated with better OS: CD3+ &gt;&thinsp;0.10% (5-year OS 63.3% vs. 13.6% if &le;&thinsp;0.10%, p&nbsp;=&thinsp;0.001); CD8+ &gt;&thinsp;0.10% (56.2% vs. 28.6% if &le;&thinsp;0.10%, p&nbsp;=&thinsp;0.051); Foxp3+ absent (59.4% vs. 16.0% if present, p&nbsp;=&thinsp;0.049). CD4+ and CD68+ infiltrates were not associated with OS. Three-year OS rates in patients with 0, 1, and &ge;&thinsp;2 negative prognostic factors were 73.6%, 47.3%, and 14.3%, respectively (p&nbsp;&lt;&thinsp;0.001). CD3+ infiltrate stratified prognosis in T1 tumors (3-year OS 71.7% if CD3+ &gt;&thinsp;0.10% vs. 14.3% if &le;&thinsp;0.10%, p&nbsp;&lt;&thinsp;0.001).</p> <p>CONCLUSIONS:</p> <p>Tumor-infiltrating lymphocytes are associated with prognosis of ICC patients after complete surgery. CD3+ and CD8+ infiltrate is associated with higher survival and lower recurrence risk, while Foxp3+ infiltrate is associated with worse prognosis. CD3+ infiltrate allows refining prediction of prognosis in early tumors.</p>